Indian price hit overstated, say pro health groups
This article was originally published in Scrip
Executive Summary
Health activist groups have slammed the pharmaceutical industry's alleged attempts to exaggerate the impact of the recent round of price caps imposed by India's apex pricing regulator and have instead furnished "evidence" that justifies a further lowering of prices.